Ketan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.
Ketan K. Badani, MD
Advertisement
Ketan Badani, MD, is a professor of urology at Icahn School of Medicine at Mount Sinai, New York, NY.
Articles by Ketan K. Badani, MD
Advertisement
Latest Updated Articles
Exploring Therapies in Combination With Cytoreductive Nephrectomy in RCCPublished: November 5th 2020 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
